Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

[1]  F. Hofmann,et al.  Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain , 2011, Clinical & Experimental Metastasis.

[2]  Anindita Das,et al.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. , 2012, Journal of the American College of Cardiology.

[3]  F. Fedele,et al.  Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging , 2012, Circulation.

[4]  H. Haider,et al.  Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction. , 2012, American journal of physiology. Heart and circulatory physiology.

[5]  B. Gage,et al.  Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis , 2012, Circulation.

[6]  R. Kloner,et al.  Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure? , 2012, Circulation.

[7]  Sang-Eun Lee,et al.  Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity , 2012, Circulation.

[8]  S. Harding,et al.  Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. , 2012, Life sciences.

[9]  J. Rychik,et al.  Impact of Sildenafil on Echocardiographic Indices of Myocardial Performance After the Fontan Operation , 2012, Pediatric Cardiology.

[10]  Saisudha Koka,et al.  Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts , 2012, Basic Research in Cardiology.

[11]  D. Kass,et al.  Preconditioning by Phosphodiesterase‐5 Inhibition Improves Therapeutic Efficacy of Adipose‐Derived Stem Cells Following Myocardial Infarction in Mice , 2012, Stem cells.

[12]  R. Arena,et al.  Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long‐term cardiopulmonary exercise testing placebo‐controlled study , 2012, European journal of heart failure.

[13]  B. French,et al.  Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium , 2012, Circulation. Heart failure.

[14]  W. Linke,et al.  Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo , 2011, Circulation.

[15]  S. Chan,et al.  PDE1 isozymes, key regulators of pathological vascular remodeling. , 2011, Current opinion in pharmacology.

[16]  L. V. von Segesser,et al.  Phosphodiesterase-5 Inhibition Mimics Intermittent Reoxygenation and Improves Cardioprotection in the Hypoxic Myocardium , 2011, PloS one.

[17]  Clint L. Miller,et al.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart , 2011, Basic Research in Cardiology.

[18]  Mark A Sussman,et al.  Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling. , 2011, Journal of molecular and cellular cardiology.

[19]  D. Kass,et al.  Phosphodiesterases and cardiac cGMP: evolving roles and controversies. , 2011, Trends in pharmacological sciences.

[20]  A. Abbate,et al.  Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. , 2011, American journal of physiology. Heart and circulatory physiology.

[21]  M. Zaccolo,et al.  cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes , 2011, Circulation research.

[22]  M. Cheitlin.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011 .

[23]  R. Arena,et al.  PDE 5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function , Cardiac Geometry , and Clinical Status in Patients With Stable Systolic Heart Failure , 2011 .

[24]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[25]  R. Fischmeister,et al.  Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes , 2010, Circulation research.

[26]  Anindita Das,et al.  Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect , 2010, Journal of Pharmacology and Experimental Therapeutics.

[27]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[28]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation Research.

[29]  Xinli Hu,et al.  Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart , 2010, Circulation.

[30]  D. Kass,et al.  Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. , 2010, Journal of molecular and cellular cardiology.

[31]  F. Hofmann,et al.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes , 2010, Proceedings of the National Academy of Sciences.

[32]  M. Nishida,et al.  Phosphorylation of TRPC6 Channels at Thr69 Is Required for Anti-hypertrophic Effects of Phosphodiesterase 5 Inhibition* , 2010, The Journal of Biological Chemistry.

[33]  Dong I. Lee,et al.  PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation , 2010, Basic Research in Cardiology.

[34]  A. Wojtovich,et al.  Role of Ca 2 (cid:1) /Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy , 2009 .

[35]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[36]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[37]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[38]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[39]  Anindita Das,et al.  Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β* , 2008, Journal of Biological Chemistry.

[40]  Anindita Das,et al.  Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. , 2007, American journal of physiology. Heart and circulatory physiology.

[41]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[42]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[43]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[44]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[45]  S. Lohmann,et al.  Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult Cardiomyocyte* , 2006, Journal of Biological Chemistry.

[46]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[47]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[48]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[49]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[50]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[51]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[52]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[53]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[54]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.

[55]  M. Guazzi,et al.  The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[56]  G. Lewis,et al.  Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension , 2004, Current heart failure reports.

[57]  F. Salloum,et al.  Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse Heart , 2003, Circulation research.

[58]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[59]  J. Corbin,et al.  Sildenafil citrate does not affect cardiac contractility in human or dog heart , 2003, Current medical research and opinion.

[60]  F. Salloum,et al.  Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. , 2002, American journal of physiology. Heart and circulatory physiology.

[61]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[63]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.